Cincinnati startup gets key FDA approval for potential Covid-19 therapy

Developing a new class of biologics to break the cycle of injury and inflammation

A Greater Cincinnati biopharma startup that’s developing new interventions for acute and chronic lung diseases this week received another key U.S. Food and Drug Administration approval.

Click here to read the complete story.

Story excerpt provided by Cincinnati Business Courier.

Written by Liz Engel.

Originally published April 12, 2021.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: